Walleye Trading LLC Uni Qure N.V. Put Options Transaction History

Walleye Trading LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $113,163 - $166,227	-20,100 Reduced 78.82%	5,400 $36,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $101,992 - $179,816	15,200 Added 147.57%	25,500 $171,000
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $71,168 - $142,080	-6,400 Reduced 38.32%	10,300 $118,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $312,290 - $385,269	16,700 New	16,700 $336,000
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $39,578 - $52,425	-1,100 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $72,096 - $108,383	-1,600 Reduced 59.26%	1,100 $50,000
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $104,026 - $192,322	2,600 Added 2600.0%	2,700 $128,000
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $44,556 - $89,544	-1,200 Reduced 92.31%	100 $7,000
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $21,104 - $32,876	400 Added 44.44%	1,300 $102,000
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $24,651 - $61,569	900 New	900 $54,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.